



## Ocular Therapeutix™ to Present at the H.C. Wainwright 20th Annual Global Investment Conference

August 29, 2018

BEDFORD, Mass.--(BUSINESS WIRE)--Aug. 29, 2018-- Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will present at the H.C. Wainwright 20th Annual Global Investment Conference on Thursday, September 6, 2018 at 1:45 PM ET at the St. Regis New York Hotel in New York, NY.

In addition to the presentation, the management team will host investor meetings at the conference. Investors attending the conference who are interested in meeting with Ocular Therapeutix management should contact their H.C. Wainwright representative.

A live webcast of the presentation can be accessed by visiting the Investors section of the Company's website at [investors.ocutx.com](http://investors.ocutx.com).

### About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix's lead product candidate, DEXTENZA® (dexamethasone insert), has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. The New Drug Application (NDA) for DEXTENZA has a target action date under the FDA Prescription Drug User Fee Act, or PDUFA, of December 28, 2018. OTX-TP (travoprost insert) is an intracanalicular insert in Phase 3 clinical development for the reduction of intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension. The Company's earlier stage assets include OTX-TIC, an extended-delivery travoprost intracameral implant for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal implants for the treatment of retinal diseases. These intravitreal implants include the development of OTX-TKI, a tyrosine kinase inhibitor (TKI), and, in collaboration with Regeneron, OTX-IVT, an extended-delivery protein-based anti-vascular endothelial growth factor (VEGF) trap. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180829005130/en/>

Source: Ocular Therapeutix, Inc.

### Investors

Ocular Therapeutix  
Donald Notman  
Chief Financial Officer  
[dnotman@ocutx.com](mailto:dnotman@ocutx.com)

or

Westwicke Partners  
Chris Brinzey, 339-970-2843  
[chris.brinzey@westwicke.com](mailto:chris.brinzey@westwicke.com)

or

### Media

Ocular Therapeutix  
Scott Corning  
Senior Vice President, Commercial  
[scorning@ocutx.com](mailto:scorning@ocutx.com)